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ABSTRACT 
Background: Recent work demonstrated that the gait of people with mild cognitive 
impairment (MCI) differs from that of age-matched controls and, in general, that walking 
ability, as measured in the clinic, does not necessarily reflect actual, daily performance. We 
evaluated if the quantity and quality of everyday walking (i.e., community ambulation) 
differs in older adults with MCI, compared to age-matched controls. 
Methods: Inclusion criteria included: age 65-90 years, able to walk at least 5 minutes 
unassisted, and >2 falls in the past 6 months. Subjects with MCI were included if they scored 
0.5 on the Clinical Dementia Rating Scale. To assess stepping quantity and quality, subjects 
wore a tri-axial accelerometer on the lower-back for 7 days. 
Results: Age and gender were similar (p>0.10) in MCI (n=36, 77.8±6.4 yrs; 27.8% men) and 
controls (n=100, 76.0±6.2 yrs; 22.0% men). As expected, Montreal Cognitive Assessment 
scores were lower (p<0.001) in MCI (21.31±4.05), compared to controls (25.81±2.64). 
Walking time was lower (p=0.016) in MCI (0.74±0.48 hrs/day), compared to controls 
(1.05±0.66 hrs/day). Within-bout walking (e.g., stride regularity) was less consistent 
(p=0.024) in MCI (0.51±0.14), compared to controls (0.58±0.14). Changes in stride regularity 
across bouts were lower (p<0.001) in MCI (0.13±0.04), compared to controls (0.17±0.01). 
Conclusions: Older adults with MCI walk less and with a more variable within-bout and less 
variable across-bout walking pattern, as compared to cognitively-intact subjects matched with 
respect to age and gender. These findings extend previous clinical work and suggest that MCI 
affects both the quantity and quality of community ambulation. 
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INTRODUCTION 
Cognitive deficits are the hallmark of mild cognitive impairment (MCI), a translational state 
between normal aging and dementia. Nonetheless, balance, gait and mobility are also altered 
in older adults with MCI (1, 2). Compared to controls, gait speed is reduced and gait 
variability is increased in older adults with MCI (3-5). In addition, gait apparently helps to 
predict cognitive decline and dementia (5-10), underscoring the relationship between motor 
and cognitive function in aging. While there is some indication that daily physical activity is 
also altered in MCI and that these changes may assist with the prediction of cognitive decline 
(11), little is known about the everyday, community ambulation stepping patterns of older 
adults with MCI. 
Recent work demonstrated that the one-time assessment of gait and mobility in the clinic, i.e., 
mobility capacity, is only modestly correlated with daily life mobility function (12-16). At 
the same time, measures of daily life mobility function may help to capture risk of falls and 
neurodegeneration that are not reflected in a conventional, one-time clinical assessment of 
mobility (14-16). Based on these reports, we speculated that the everyday stepping pattern 
might also be affected by MCI. In this exploratory study, we addressed the following 
questions: 1) Is the amount of daily-living walking different in older adults with MCI and 
age-matched controls? 2) Is the quality of the walking pattern different in older adults with 
MCI and controls? and 3) Is everyday walking mobility related to performance on clinical 
tests of gait and balance? 
 
METHODS 
Participants 
The present analysis is based on the baseline assessment of subjects who participated in a 
randomized controlled trial designed to reduce fall rates in older adults (17, 18). Briefly, 
older adults at five clinical centers across five countries (Belgium, Israel, Italy, the 
Netherlands, and UK) were studied. Subjects were included if they were: a) age 65-90 years, 
b) self-report ability to walk at least 5 minutes unassisted, c) on stable medications, and d) 
had at least 2 falls in the previous 6 month, a requirement of the parent study, the RCT. 
Subjects with MCI were included if they scored 0.5 on the Clinical Dementia Rating Scale. 
Subjects were excluded if they had other significant comorbidities or clinical diagnosis of 
dementia or severe cognitive impairment. 
For example, subjects were excluded if they had psychiatric co-morbidity (e.g., major 
depressive disorder as determined by DSM IV criteria), clinical diagnosis of dementia or 
other severe cognitive impairment, history of stroke, traumatic brain injury, Parkinson's 
disease, or other neurological disorders (other than MCI, for that group), acute lower back or 
lower extremity pain, peripheral neuropathy, rheumatic and orthopaedic diseases, or if they 
had an unstable medical condition including cardiovascular instability in the past 6 months. 
In addition, to avoid complications due to wear time of the accelerometer, we only included 
subjects with 7 day recordings. The study was approved by each clinical site’s ethics 
committee. All participants provided informed written consent prior to testing. 
 
Demographics and lab-based measures 
Age and sex were recorded for each participant along with other subject characteristics. The 
Montreal Cognitive Assessment (MOCA) evaluated general cognitive function and sub-items 
were used to estimate visualspatial/executive function and attention. Gait speed, stride length, 
and stride time variability were measured during usual walking and the SF-36 was used to 
evaluate general health and physical function (17). The Short Physical Performance Battery, 
the two minute walk test, Mini-Balance Evaluation Systems Tests, and the Four Square Step 
Test assessed different aspects of balance, gait and mobility capacity in the lab (17). 
Everyday walking data collection 
At the end of the laboratory testing session, participants wore a water-proof, tri-axial 
accelerometer (Axivity AX3, York, UK; 23.0×32.5×7.6 mm; weight: 11 grams; 100 Hz 
sampling rate) for one week. The accelerometer was placed on the fifth lumbar vertebrae, 
held in place with a hydrogel adhesive, and covered with a Hypafix bandage. Participants 
were asked to continue their activities as usual. Upon completion of the recording, 
participants removed the device and sent it back to the local clinical site. 
As previously described, we identified each bout of walking (as well as lying, standing, and 
sitting) throughout the week-long recording and then extracted measures that reflect the 
quantity and quality of walking (14, 15). To focus on steady-state walking and to compare in-
lab walking with community ambulation, we focused on bouts that were at least 60 seconds 
long (14, 15). To evaluate the quality of the walking pattern, we extracted the step regularity 
and the peak value of the Fourier transformed acceleration in the vertical direction in each 
bout (14, 15); for both metrics, higher values reflect greater walking consistency. These 
measures can be determined without the need to identify individual steps and are related to 
the known increase in gait variability in MCI. Each subject’s median value over the week was 
determined. In addition, to assess bout-to-bout variations over the week, we calculated the 
standard deviation of these two measures of walking quality for each subject. 
 
Statistical analysis 
Normality of data was tested with a Shapiro-Wilk test. Descriptive statistics are reported as 
means and standard deviations (SD). Spearman’s correlations assessed the relationship 
between measures and multiple regression analyses evaluated the effect of covariates and the 
independence of measures. For the within-bout and across-bout measures of community 
ambulation walking quality, we used a Bonferonni corrected cut-off of p=0.025 to define the 
level of significance; otherwise, a two-tailed p-value < 0.05 was considered statistically 
significant. Cohen’s d was used to estimate effect size of group differences. Statistical 
analyses were performed using SPSS Version 22 (SPSS Inc.). 
 
RESULTS 
Age, sex, height, weight, body-mass-index and general health were similar in the two groups 
(Table 1). As expected, MOCA scores were lower in the MCI group. Measures of gait and 
mobility capacity, i.e., when tested in the lab, were worse or tended to be worse in the 
subjects with MCI, compared to the controls (Table 2). 
Figure 1A shows an example of the bar code summary of the walking and other bouts 
recorded in an example subject with MCI and a control subject. As seen in this example, on a 
group level, the MCI group spent less time walking, as compared to the controls (see Table 
3). Figure 1B-D shows an example walking bout of a subject with MCI and a control subject, 
along with the corresponding autocorrelation plot and frequency domain analyses. Stride time 
regularity and the peak in the frequency domain were lower in the subject with MCI, as 
compared to the control subject. Similar results were seen on a group level (see Table 3). 
Within bout walking consistency, as measured by both stride regularity and the peak in the 
frequency domain, were significantly lower in the MCI subjects than in the controls. For both 
measures of stepping quality, the across bout variability was lower in the subjects with MCI, 
compared to the controls (see Table 3). 
The correlations between the mobility capacity and mobility function measures were 
generally modest to moderate (see Figure 2), suggesting that the mobility function measures 
captured different aspects of mobility than the in-lab, one-time measures. This possibility was 
also explored using multiple regression analyses. When included in the same regression 
model, measures of mobility capacity and mobility function were both independently 
associated with group assignment (i.e., MCI vs. controls). For example, the Four Square Step 
Test (p=0.025) and the SD of the peak amplitude (p=0.005) were both related to group (i.e., 
MCI vs. controls). 
Finally, we explored if the observed group differences in everyday stepping were related to 
cognitive function. When MOCA scores were added to the regression models, several of the 
group differences in everyday walking were no longer significant (see Table 3), suggesting 
the cognitive function may have influenced or mediated the across group changes in everyday 
stepping. We also explored if MCI subtype (amnestic vs. non-amnestic) might impact the 
stepping measures by dividing the subjects into those who scored above or below the MCI 
group’s median value (and into a tertile split, comparing the worst and best groups) for 
visualspatial/ executive and attention sub-scores. There were no differences in the everyday 
walking pattern between these sub-groups both for the visualspatial/executive items and the 
attention items (p>0.47). 
 
DISCUSSION 
Consistent with previous findings (1-5), we observed that older adults with MCI performed 
poorer on in-lab measures of balance, gait and mobility than age-matched older adults who 
did not have MCI or dementia. Here, we find that not only is mobility capacity altered, but 
mobility function, as reflected in daily life ambulation, is also changed in MCI. Everyday 
stepping quantity and stepping quality were reduced in MCI, compared to age-matched 
controls. In addition, mobility capacity and mobility function were only moderately related to 
each other, similar to findings in other cohorts (12-16). We also found that measures of 
mobility capacity and function were independently associated with group assignment. Taken 
together, these results suggest that measures of everyday walking reflect aspects of mobility 
that are not simply a mirror-image of the gait and balance changes measured in the lab 
setting. Interestingly, while MCI is conventionally defined by a lack of impact of the 
cognitive changes on activities of daily living, the present findings suggest that subtle, but 
measurable changes in everyday ambulation can be detected in MCI. 
Several hypotheses putatively explain the association between gait changes, as measured in 
the lab, and cognitive impairment in older adults, in MCI, and in dementia (1-5). Some 
suggest that the relationship is simply a manifestation of changes in brain areas common to 
both the control of walking and to cognitive functioning. For example, reduced grey and 
white matter volumes and white matter hyper-intensities are observed in brain regions that 
contribute to gait dysfunction and to cognitive deficits. There is, however, increasing 
evidence that gait in aging relies on specific, higher-level cognitive functioning and that 
deficits in these brain regions (e.g., dorsal lateral pre-frontal cortex) contribute to the gait 
changes seen in MCI and dementia (7, 19). 
The present work was not designed to probe mechanisms. Still, we found that changes in 
everyday (within-bout) walking consistency were no longer significant in models that 
adjusted for MOCA scores and that the everyday walking measures were only moderately 
correlated with in-lab measures. These findings suggest that brain regions and networks 
related to cognitive function are likely involved in the observed changes in daily walking and, 
further, that the specific mechanisms that contribute to changes in community ambulation are 
not identical to those that contribute to the changes quantified in the lab-setting. Perhaps 
other factors that were not measured (e.g., affect) explain these findings. Future work is 
needed to assess this question. 
The present study has several limitations. For example, we used the Clinical Dementia Rating 
Scale to identify subjects with MCI, while other criteria are available. Our use of this 
definition may affect generalizability. In the future, it will be interesting to see if the observed 
findings are affected by the exact definition of MCI and if the results vary with MCI-subtype 
(e.g., amnestic vs. non-amnestic). In exploratory analyses, when the MCI subjects were 
divided into those with relatively better or worse visualspatial/executive function or attention, 
there were no differences in everyday walking. suggesting that the results may be insensitive 
to MCI type. Still, a larger sample and other ways of characterizing subjects as amnestic or 
non-amnestic should be investigated in the future. Because subjects in the present study were 
recruited to participate in a falls intervention study, all of the subjects had a history of 
multiple falls. While this history was controlled for in that subjects in both groups met this 
criteria, and falls are common in MCI (20), in the future, it will be important to assess 
whether the observed findings generalize to people with MCI who do not have a history of 
falls. The cross sectional nature of the present analyses also needs to be kept in mind. Finally, 
while we applied previously validated methods to detect everyday walking (14, 15), it is 
possible that other activities may have been identified as walking. 
The present findings suggest that everyday stepping quantity and stepping quality, both 
within and across bout metrics, are related to MCI and are not strongly related to in-lab 
measures of gait and balance. Prospective studies are needed to determine if and how these 
measures of everyday walking can augment the prediction of cognitive decline and the 
progression to dementia, potentially addressing the need for additional markers of future 
cognitive impairment in older adults (7, 19, 20). 
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Table 1: Subject characteristics 
 
 Controls 
(n=100) 
 
MCI 
(n=36) 
 
P-value 
Age (yrs) 76.0±6.2  77.8±6.4 0.145 
Gender (% men) 22.0%  27.8% 0.506 
Education (yrs) 13.4±3.9  10.9±2.9 <0.001 
Height (m) 1.65±0.01 1.64±0.08 0.897 
Weight (kg) 70.5±13.4  70.9±13.9 0.883 
Body-mass-index (kg/m2)  25.9±4.2  26.2±4.6 0.787 
Montreal Cognitive Assessment: 
Total score 
25.8±2.6  
 
21.3±4.1 <0.001 
Montreal Cognitive Assessment: 
visuospatial/executive score 
4.13±0.1  3.11±0.21 <0.00001 
Montreal Cognitive Assessment: 
Attention score 
5.65±0.6 4.89±0.21 <0.001 
Number of falls (in past 6 
months) 
2.96± 2.14 2.08±0.68 0.166 
SF-36 General Health 62.12±1.94  57.90±3.48 0.143 
SF-36 Total Physical Health 62.97±1.73 58.71±3.04 0.221 
SF-36 Physical Function 67.75±2.38 60.15±4.28 0.188 
 
 
 
  
 
  
 
 
Table 2: In lab measures of gait and mobility capacity 
 
 Controls 
(n=100) 
 
MCI 
(n=36) 
 
P-value Effect 
Size 
 
Gait speed (m/sec) 1.06±0.24  0.90±0.29 0.017 0.601 
Stride Length (m) 1.16±0.20 1.02±0.22 0.004 0.666 
Stride time variability (%)  2.24±1.92 2.78±2.35 0.117 0.252 
Short Physical Performance 
Battery (SPPB) 
9.42±2.03  
 
8.44±2.74 0.070 0.406 
Mini Best test of balance 
(MiniBest) 
 
23.0±5.87 19.8±6.4 0.008 0.521 
Two min walk distance (m) 133.1±32.0 118.2±33.1 0.019 0.457 
Four Square Step Test (sec) 
(FSST) 
 
11.2±5.1  
 
15.7±10.1 0.002 0.562 
 
 
 
Table 3: Measures of mobility function derived from the 7 day recordings 
 
  Controls 
(n=100) 
 
MCI 
(n=36) 
 
P-value Effect 
Size 
 
Walking 
quantity 
 
Time spent 
walking (hrs/day) 
[from walking 
bouts≥60 sec] 
 
1.05±0.66  
 
0.74±0.48 0.016 b 0.537 
Within Bout 
Walking 
Quality 
 
Stride Regularity 
(unitless) 
 
0.58±0.14  
 
0.51±0.14 0.024 0.500 
Peak amplitude 
(g2/Hz) 
 
0.72±0.21  
 
0.62±0.21 0.015 0.476 
Across Bout 
Variability of 
Walking 
Quality 
 
SD of stride 
regularity (unitless) 
 
0.17±0.01  
 
0.13±0.04 <0.001 a, b, c 1.372 
SD of peak 
amplitude (g2/Hz) 
 
0.18±0.01  
 
0.12±0.05 <0.001 a, b, 
c 
1.664 
a, b, c: Group differences persisted after adjusting for the MOCA total score (or the 
visuospatial/executive score or attention score; all 3 MOCA scores behaved similarly), years 
of education and two minute walk distance (a proxy for cardiovasvular function), 
respectively. 
 
FIGURES 
 
 
Figure 1: Example steps in the processing of the 7 day accelerometer data for a subject with 
MCI and a control subject. A) Barcode plot illustrating daily activity for one day; B) Raw 
vertical acceleration signal in one bout of walking; C) Autocorrelation plot used to determine 
stride regularity in a bout; D) Frequency domain plot used to determine the peak in the 
frequency domain for a bout of walking. 
 
  
 
Figure 2: Heat map showing the Spearman correlation coefficients between measures of 
mobility capacity (i.e., those measured in the lab) and mobility function (metrics derived 
from the 7 day recordings). Darker pixels reflect higher correlation values. Note that while 
the mobility capacity measures tended to be moderate to highly correlated with each other, 
they were not strongly correlated with the mobility function measures (see, for example, the 
top left quadrant of the map). Stride reg: stride regularity; amp: amplitude. 
 
